Patience and adherence to your treatment plan are key, as the most meaningful benefits generally develop gradually over the first few weeks
Factors influencing the blood-brain barrier permeability
(): 18 HHT patients treated with direct PuraBond application to nasal telangiectasias Improved Epistaxis Severity Scores No adverse events, allergic reactions, or pain reported Less crusting and healthier-appearing mucosa at follow-up (): 985 patients undergoing turbinate reduction, with or without PuraBond Crusting reduced Mucosal re-epithelialisation observed Reliable haemostasis and reduced post-op bleed rates No product-related complications Rather than replacing existing methods, PuraBond is being integrated into ENT practice to help support haemostasis, protect fragile mucosa, and reduce procedural trauma, especially in patients with underlying vascular fragility like HHT
Click to expand
These injections are a generic form of FDA-approved medications that were originally developed to help manage and control Type 2 Diabetes
Given the lack of evidence on safety and long-term use, thats a real concern. Health officials consider loosening peptide regulations In 2023, the FDA changed its classification of some of the most popular peptides including BPC-157, TB-500, CJC-1295 and Ipamorelin citing safety concerns and a lack of evidence